Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of EVP-6124 in mild to moderate Alzheimer's disease
NL-OMON40480Phase 3Active, not recruiting
- Sponsor
- FORUM Pharmaceuticals
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of encenicline in Alzheimer's disease (AD) (3 arms), sponsored by FORUM Pharmaceuticals. Primary endpoints: Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 13-item, Change from baseline in Clinical Dementia Rating Sum of the Boxes and 1 more. Started Jun 2014; status: active, not recruiting.
02
Drugs
encenicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON40480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40480.